title: Pharmacokinetics after intravenous administration of flunixin meglumine in budgerigars (Melopsittacus undulatus) and Patagonian conures (Cyanoliseus patagonus).
abstract: OBJECTIVE
  To investigate the disposition kinetics of flunixin meglumine when administered IV to budgerigars (Melopsittacus undulatus) and Patagonian conures (Cyanoliseus patagonus).
  
  
  METHODS
  Prospective cohort study.
  
  
  METHODS
  8 adult Patagonian conures and 24 adult budgerigars.
  
  
  METHODS
  Injectable flunixin meglumine (50 mg/mL) was diluted to 10 and 1. 0 mg/mL and administered IV at a dose of 5.0 mg/kg (2.3 mg/lb) to Patagonian conures and budgerigars, respectively.
  
  
  RESULTS
  In budgerigars, the elimination half-life was 0.72 hours and the mean residence time was 0.73 hours. In Patagonian conures, the elimination half-life was 0.91 hours and the mean residence time was 1.20 hours. The concentration of flunixin was below the assay's limit of quantification (0.5 μg/mL) at 3 and 6 hours in budgerigars and Patagonian conures, respectively. A single budgerigar developed adverse effects (lethargy and signs of depression) for approximately 15 minutes following drug administration.
  
  
  CONCLUSIONS
  The half-life of flunixin in Patagonian conures and budgerigars was short following IV administration; however, results of this study suggested that IV administration of injectable flunixin meglumine at 5.0 mg/kg resulted in plasma concentrations that could potentially be anti-inflammatory and analgesic in budgerigars and Patagonian conures.
authors.affiliation: Schubot Exotic Bird Health Center, College of Veterinary Medicine, Texas A&M University, College Station, TX 77843, USA. jmusser@cvm.tamu.edu
authors.forename: Jeffrey M B
authors.initials: JM
authors.lastname: Musser
authors.forename: J Jill
authors.initials: JJ
authors.lastname: Heatley
authors.forename: David N
authors.initials: DN
authors.lastname: Phalen
mesh_terms: D000818:Animals; D019540:Area Under Curve; D003002:Clonixin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics; D006207:Half-Life; D011448:Prostaglandin Antagonists / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D011563:Psittaciformes / Q000097:blood*; D013045:Species Specificity
chemical_list: D011448:Prostaglandin Antagonists; C014558:flunixin meglumine; D003002:Clonixin